Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CareMore-Trastuzumab in HER2-negative primary breast cancer with HER2-positive circulating tumor cells
2014-004432-18Phase 2Active
- Sponsor
- Erasmus MC Cancer Institute
- Start
- Nov 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and docetaxel in breast cancer, sponsored by Erasmus MC Cancer Institute. Primary endpoint: Progression-free survival rate at 6 months. Started Nov 2014; status: active.
02
Drugs
trastuzumabdocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-004432-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004432-18.